Biotech partnership may lead to merger

Guest Contributor
January 26, 2016

Two privately held Vancouver biotech firms have entered a strategic partnership that could lead to an eventual merger. Zymeworks Inc has made an equity investment in Kairos Therapeutics Inc — a spin off of the Centre for Drug Research and Development. Zymeworks specializes in bi-specific and multi-specific anybodies while Cairos discovers and develops antibody drug conjugates. The partnership will allow the companies to explore the advantages of a merger on accelerating their respective platforms, resources and pipelines....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.